UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): March 12, 2018

Codexis, Inc.

(Exact name of Registrant as Specified in its Charter)

Delaware	**001-34705**	**71-0872999**
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

200 Penobscot Drive
Redwood City, CA 94063
(Address of Principal Executive Offices) (Zip Code)

(650) 421-8100
(Registrant's telephone number, including area code)

Not Applicable
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- ☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On March 12, 2018, Codexis, Inc. (the "Company") updated its corporate presentation (the "Corporate Presentation") in connection with upcoming investor conferences. A copy of the Corporate Presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K, and incorporated by reference herein.

The information furnished in this Current Report on Form 8-K pursuant to Item 7.01 (including Exhibit 99.1) shall not be deemed to be "filed" under the Securities Exchange Act of 1934, as amended, nor shall it be incorporated into any future filing under the Securities Act of 1933, as amended, or under the Securities Exchange Act of 1934, as amended, unless the Company expressly sets forth in such future filing that such information is to be considered "filed" or incorporated by reference therein.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
99.1	Corporate presentation of Codexis, Inc.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 12, 2018

CODEXIS, INC.

By: /s/ Gordon Sangster
Name: Gordon Sangster
Title: Senior Vice President and Chief Financial Officer

EXHIBIT INDEX

Exhibit No.	Exhibit Description
99.1	Corporate presentation of Codexis, Inc.



CODEXIS®
PROTEIN ENGINEERING EXPERTS™

March 2018

Codexis Corporate Presentation
Nasdaq: CDXS

Forward-Looking Statements

- These slides and the accompanying oral presentation contain forward-looking statements that involve risks and uncertainties. These statements relate to future events or our future financial or operational performance and involve known and unknown risks, uncertainties and other factors that could cause our actual results, levels of activity, performance or achievement to differ materially from those expressed or implied by these forward-looking statements. Forward-looking statements include all statements that are not historical facts. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "could," "would," "expects," "plans," "anticipates," "believes," "estimates," "projects," "predicts," "potential" or the negative of these terms, and similar expressions and comparable terminology intended to identify forward-looking statements. These forward-looking statements represent our estimates and assumptions only as of the date hereof, and, except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
- Other factors that could materially affect actual results, levels of activity, performance or achievement can be found in Codexis' Form 10-K for the period ended December 31, 2016 filed with the SEC on March 9, 2017 and Form 10-Qs filed with the SEC on May 9, 2017, August 9, 2017 and November 9, 2017, including under the caption "Risk Factors." If any of these risks or uncertainties materialize, or if our underlying assumptions prove to be incorrect, actual results, levels of activity, performance or achievement may vary significantly from what we projected.
- Our logo, "Codexis," "CodeEvolver®," and other trademarks or service marks of Codexis, Inc. appearing in this presentation are the property of Codexis, Inc. This presentation contains additional trade names, trademarks and service marks of other companies. We do not intend our use or display of other companies' trade names, trademarks or service marks to imply relationships with, or endorsement or sponsorship of us by, these other companies.

CODEXIS®
PROTEIN ENGINEERING EXPERTS™

Codexis – Unlocking the Power of Proteins™

Company History
16+ Years

Employees
~120 (70 in R&D)

Cumulative Investments
> $500m

Patents & Applications
> 1100 worldwide

2018 Revenues (Forecast)
Total = $60-63 million
5Yr CAGR: 13-15%

CODEXIS®
PROTEIN ENGINEERING EXPERTS™

Proteins – Infinite Source of New Value Creating Materials



CODEXIS®
PROTEIN ENGINEERING EXPERTS™

Complexity of Protein Structure - Function Relationships

DNA Code

Protein Structure



Protein Function



Codexis Uniquely Mapping This Big Data Landscape

CODEXIS®
PROTEIN ENGINEERING EXPERTS™

CodeEvolver®: World-Leading Protein Engineering Platform



Starting protein from Codexis libraries and/or *in silico* designed

CodeEvolver®'s artificial intelligent algorithms learn structure – function relationships from vast data generated

Identifying new protein libraries that accelerate toward targeted protein function enrichments









Automated gene synthesis, protein production, performance testing and sequencing of tens of thousands of identified proteins per round per project



CodeEvolver® Engineered Protein

CODEXIS®
PROTEIN ENGINEERING EXPERTS™

For more on CodeEvolver®: https://youtu.be/xSW0UDlgWRI https://youtu.be/up5QUdTLsBU

Radical Protein Overhauls Are Required

Extent of Protein Engineering Needed to Displace Incumbent Products

THIS is what CodeEvolver® Routinely Delivers

CODEXIS®
PROTEIN ENGINEERING EXPERTS™

With Accelerating Speed & Shrinking R&D Costs

Sources of CodeEvolver®'s Accelerating Speed

- Expanding libraries of better performing starter proteins
- Proprietary artificial intelligence algorithms machine learn how to predict protein function more accurately
- Automated real-world protein production and performance testing in high-throughput gets faster and cheaper



CODEXIS®
PROTEIN ENGINEERING EXPERTS™

Accelerating Protein Targets Leveraging CodeEvolver®



CODEXIS®
PROTEIN ENGINEERING EXPERTS™

1) Codexis estimates
2) Markets and Markets Report FB2277, Oct 2016
3) Mordor Intelligence, https://goo.gl/3867rV, Sep 2016

Codexis Protein Businesses Leveraging CodeEvolver®

Protein Catalysts for Pharma Manufacturing

Solid, Accelerating Financial Base

CODEXIS®
PROTEIN ENGINEERING EXPERTS™

Codexis: A Leader in Pharma Protein Catalysts



Merck's Januvia®

Codexis' Award Winning Pharma Process Commercialization

" ...[Codexis] helped avoid the cost of building a 2nd factory to meet the rising demand for Januvia®."

Skip Volante, Merck VP R&D

- ✓ ZERO activity from all starter protein sources
- ✓ > 10%: higher yield / lower waste & energy
- ✓ > 50% higher volumetric productivity
- ✓ Stable in high temp + high organic solvent load
- ✓ Expensive, toxic chemo-catalyst replaced
- ✓ No new factory needed to support growth

CODEXIS®
PROTEIN ENGINEERING EXPERTS™

Protein Catalyst Processes

- *Lower impurities*
- *Higher yields*
- *Fewer process steps*
- *Less waste*
- *Energy efficient*

Winner 2006 EPA Presidential Green Chemistry Challenge Award — GREEN CHEMISTRY

Winner 2010 EPA Presidential Green Chemistry Challenge Award — GREEN CHEMISTRY

Winner 2012 EPA Presidential Green Chemistry Challenge Award — GREEN CHEMISTRY

Pharma Protein Catalyst Business: Solid, Accelerating Financial Base

Acceleration of core P&L measures

Momentum of Codexis catalyst installations

Deeper R&D access deals with elite customers

Platform deals' 100% margin backends kick in

Protein Catalyst Pharma Penetration Metrics	2016	2017	2018 (forecast)
Product Sales ($m/yr) [1]	~ $15	~ $24m	+
Gross Margin on Product Sales (%) [2]	36%	46%	
# Pharma Customer's Products Using > $500k of Product [1]	4	12	
# API's Commercially Using Codexis [3]	7	7	
Pre-commercial (phase 2 or later) Pipeline Projects [3]	10	15	
# Pharma Customers w/ Dedicated Protein Engineer Teams	1	3	
# Pharma Customers w/ CodeEvolver® Platform License	2	2	
# CodeEvolver® Licensees Generating > $1m Backends	0	0	1

CODEXIS®
PROTEIN ENGINEERING EXPERTS™

1) Excludes product sales into food application
2) Gross margin on all product sales (includes sales into food)
3) See pipeline snapshot appendix; first three pharmaceutical manufacturing rows only

Codexis Protein Businesses Leveraging CodeEvolver®



CODEXIS®
PROTEIN ENGINEERING EXPERTS™

Bring CodeEvolver® Improved Enzymes To Large Existing Markets



Detergents

~ $5 Billion Industrial Enzyme Sectors

Molecular Diagnostics & Biology

Food and Nutrition

Chemicals & Energy

Animal Feed & Health

Flavors and Fragrances

CODEXIS®
PROTEIN ENGINEERING EXPERTS™

Fast Enzyme Commercializations in New Industrial Verticals

Codexis Novel Enzymes Enable Tate & Lyle's Food Ingredient Innovations

- 2014: 7 months of CodeEvolver® protein engineering drove 10-fold reduction in catalyst cost
- 2015: Lower cost enables Tate & Lyle to launch its new food ingredient
- 2017: Sales to T&L for this application are Codexis 2nd largest product sale
- 2017: Codexis and Tate & Lyle strike second deal to enable a second, larger new food ingredient
- 2018: 2nd project's enzymes scaling for GRAS affirmations and T&L commercial scale trials

> 10% of Codexis sales to food industry in 2017

Codexis Novel Enzymes Enabling Enhanced Molecular Diagnostics & Biology

- 2016: Identified opportunity to bring CodeEvolver® engineered enzymes for the ~ $100m genomic diagnostic workflow market
- 2017: First enzyme, a DNA Ligase, engineered and scaled. Demonstrates 90+% conversions in 3min vs competitive enzyme at < 50% conversion in > 10 min
- 2018: DNA Ligase set for market penetration and sales
- 2018: Second, in a stream of planned enzymes being engineered and prepped for beta testing

✓ Expect another significant new deal in another industrial enzyme vertical to be executed in 2018

CODEXIS®
PROTEIN ENGINEERING EXPERTS™

Codexis Protein Businesses Leveraging CodeEvolver®



CODEXIS®
PROTEIN ENGINEERING EXPERTS™

The Opportunity for CodeEvolver® in Biotherapeutics

CodeEvolver ® Targetable BioTx Characteristics

Efficacy	Enhanced, tissue-specific activity
Safety	Reduced immunogenicity
Stability	Enhanced half-life in plasma and lysosome, stable in GI-tract
Convenience	Reduced dosing frequency, more desirable delivery (ie, oral)
Manufacturability	Optimized biophysical properties for manufacturing

Substantial Rare Disease Enzyme Targets*



Enzyme deficiencies: 147

CODEXIS®
PROTEIN ENGINEERING EXPERTS™

* http://sid.usal.es/idocs/F8/FDO26770/Prevalencia_ER_lista.pdf

Oral Enzyme For PKU Successfully Developed & Partnered

Nestlé HealthScience®

CODEXIS®
PROTEIN ENGINEERING EXPERTS™

"We have partnered with Codexis to accelerate enzyme innovation for multiple health conditions."

—Nestlé Health Science

Nestlé & Codexis Therapeutic Development Platform Access Partnership Deal (Oct 2017):

- ✓ Purchased rights to commercialize the oral PKU drug candidate
- ✓ Up to $357 million in upfront + milestones, plus up to low double digit % royalty on sales
- ✓ First look rights for Nestlé for other IEAAM programs in Codexis pipeline
- ✓ CodeEvolver® R&D capacity newly dedicated to novel breakthrough protein targets

CODEXIS®
PROTEIN ENGINEERING EXPERTS™

Setting Up For More Success From Pipeline

CodeEvolver® Generated *in vitro* Candidate Discovery	Preclinical Research	IND Enabling	Human Trials

CDX-6114: Inborn Error of Amino Acid Metabolism Disease, PKU

Codexis phase 1 trials in 2018

Nestlé HealthScience

NHSc option early 2019

- IEAAM - 2
- IEAAM - 3
- Lysosomal Storage Disease LSD-1
- LSD-2
- Discovery Partnership — Nestlé HealthScience

Two Add'l *Partnerable* Assets in 2019

+ Prospects of other significant new discovery partnering deals working CodeEvolver® into new biotherapeutic modalities (outside enzyme therapeutics)

CODEXIS®
PROTEIN ENGINEERING EXPERTS™

Codexis in 2017: Building Momentum Again

$50.0m

2017 Total Revenue

Growth Despite $22.5m in Non-recurring 2016 Revenues

✓ Met

Performance vs Annual Guidance

Fourth Consecutive Year

✓✓

2017 Strategic Deliverables

- ✓ **13 Customer Products Each Use > $500k Codexis Protein Catalysts**
- ✓ **Food Industry Generates Greater Than 10% of Revenues**
- ✓ **Three Pharma Customers Secure Dedicated Teams (up from one)**
- ✓ **Breakout New Partnering Deals Executed:**
  - *Biotherapeutics Partnership with Nestlé Health Science*
  - *Second Major Food Ingredient Partnership with Tate & Lyle*
- ✓ **MDx/NGS Enzymes Setup For Successful Market Entry**
- ✓ **Capably Building Biotherapeutic Development Capabilities:**
  - *Accelerated CDX-6114 for PKU Towards Phase 1 Trials*
  - *Four More Discovery Programs Move Towards Partnerable Status*
- ✓ **Completed $25 Million Financing to Support Growth**

$26.7m

2017 Product Sales

+74% vs 2016

46%

2017 Product Margin

Up From 36% in 2016

CODEXIS®
PROTEIN ENGINEERING EXPERTS™

Codexis 2018 Financial Outlook

Total Revenue ($ million)



2018 Annual Guidance Introduced

Total Revenues: **$60 - 63m** (+20-26% vs 2017)

Product Sales: **$25 - 28m** (2017 = $26.7m)

Product Gross Margin: **45 - 48%** (2017 = 46%)

Additional Insights Into 2018 Financial Outlook

Revenues: **~35% in 1H'18 / ~65% in 2H'18**

R&D + GS&A Expenses: **Similar To 2017; ~ Smooth Quarterly**

CODEXIS®
PROTEIN ENGINEERING EXPERTS™

Codexis Strategic Objectives for 2018

Relentless Focus on CodeEvolver® technology platform, AI-Driven Acceleration of Protein Discoveries

- ✓ Reinforce our powerful, product-commercializing uniqueness in the world's growing synthetic biology landscape

Continue Profitable Penetration of Protein Catalysis in Pharmaceutical Manufacturing

- ✓ Continue expansion of the number of our late-stage installations (Phase 2 to commercial) in our pipeline (22 as of 6/30/17)
- ✓ Deepen deployment by account: Lightly engaged → Project → Dedicated team → CodeEvolver® deal (→ 100% margin backends)
- ✓ At least one significant new deal executed in 2018

Continue to Broaden our Industrial Enzyme Capabilities Outside Pharma Manufacturing

- ✓ Food: approach commercialization of the second (larger peak rev) project with Tate & Lyle; again > 10% of total revenues
- ✓ Diagnostics/NGS: penetration / sales established with our DNA Ligase; launch at least one new product into field
- ✓ At least one significant new deal in another industrial enzyme vertical executed in 2018

Establish the Significance of our Biotherapeutics Business

- ✓ CDX-6114 For PKU: start phase 1 trial (mid-2018 - $4m cash); Nestlé Health Science option exercise (early 2019 - $3m); advances from there
- ✓ Pipeline: at least two additional lead candidates (beyond PKU) are "*partnerable*" (locked and on way to IND) by 2019
- ✓ At least one significant new deal working CodeEvolver® platform into new biotherapeutic modalities (outside enzyme therapeutics)

CODEXIS®
PROTEIN ENGINEERING EXPERTS™


CODEXIS®
PROTEIN ENGINEERING EXPERTS™
Unlock the power of proteins™
23

Contact Us

Corporate Headquarters

200 Penobscot Drive

Redwood City, CA 94063

USA

Nasdaq: **CDXS**

CODEXIS®
PROTEIN ENGINEERING EXPERTS™

John Nicols

President & Chief Executive Officer

- john.nicols@codexis.com
- (650) 421-2388

Gordon Sangster

Senior Vice President & Chief Financial Officer

- gordon.sangster@codexis.com
- (650) 421-8115

Jody Cain

Lippert Heilshorn & Associates

- Codexis Investor Relations Partner
- jcain@lhai.com
- (310) 691-7100



Appendix – Most Recent Pipeline Snapshot

CODEXIS®
PROTEIN ENGINEERING EXPERTS™

Codexis Pipeline Snapshot

Type of Protein & Target Market	Pre-Commercial		Commercial	Pipeline Total	vs. prior pipeline
	Codexis Driven		Sustaining Revenues	6/30/17	6/30/16
	Codexis Self-funded	*Customer Partnered*	*Product Sales and/or Licensing*		
Protein Catalysts Improving Pharmaceutical Manufacturing:					
Developmental Drugs in Clinical Phase II or later		10	n.a.	10	*+3*
Patented On-the-Market Drugs		1	2	3	-
Generic On-the-Market Drugs	1	3	5	9	*+2*
Expanding Industrial Enzyme Verticals:					
Protein Catalysts For Food Ingredient Manufacturing		3	1	4	-
Enzymes Enabling Molecular Diagnostic & Biology	1			1	-
Novel Biotherapeutics Discovery & Development	5	1		6	*+2*
Pipeline Total as of June 30, 2017	**7**	**18**	**8**	**33**	***+7***

CODEXIS®
PROTEIN ENGINEERING EXPERTS™

Appendix – Success Stories & Customer Testimonials

CODEXIS®
PROTEIN ENGINEERING EXPERTS™

Capital & Yield Efficiencies Unlocked For Merck's Januvia®

CHALLENGE

Capacity constraints in existing sitagliptin (active ingredient in Januvia) supply chain

SOLUTION

- Protein engineered from zero activity to commercial targets in less than 12 months
- 53% higher productivity
- 19% reduction in energy usage
- Expensive, toxic chemo-catalyst replaced
- No new factory needed to support growth

" ...[Codexis] helped avoid the cost of building a 2nd factory to meet the rising demand for Januvia®."

Skip Volante, Merck VP R&D

CODEXIS®
PROTEIN ENGINEERING EXPERTS™

Major PharmaCo Patented Drug Process Overhaul



CHALLENGE

Inefficient patented drug manufacturing process affecting Top-10 global pharma company's profit margins

SOLUTION

- Prior protein libraries: zero activity
- 43 sequence variations required
- Engineered protein results in > 3x lower cost than customer's target
- Engineered protein's temperature stability to fit reaction conditions
- Expensive, toxic chemo-catalyst replaced

Phase II+ Drug Processes Overhauled By Codexis Protein Catalysts: 22 & counting

CODEXIS®
PROTEIN ENGINEERING EXPERTS™

CodeEvolver® Licensing Creates Value Across GSK's Portfolio

CHALLENGE

How to effectively leverage protein engineering widely across GSK's portfolio?

SOLUTION

- Licensed the CodeEvolver® platform
- Deeply embedded the technology in house
- Applications from discovery to post launch
- Codexis earns front end and back end economics
- Partnership created around shared vision for proteins and mutual success of CodeEvolver®

"We chose the Codexis platform after a thorough evaluation of the enzyme evolution landscape..."
Doug Fuerst, GSK Technology Development Lead, Synthetic Biology

CODEXIS®
PROTEIN ENGINEERING EXPERTS™

Tate & Lyle's New Food Ingredient Launch Enabled



CHALLENGE

Healthier food ingredient requires a lower cost process to enable the product launch

SOLUTION

- Protein catalyst system engineered to meet commercial targets in less than 7 months
- 20-fold catalyst stability improvement
- 90+% reduction in catalyst system cost
- Enabled commercial production of the healthy ingredient < 2 years after 1st project discussion

"We view Codexis as an extension of our internal R&D programs at Tate & Lyle..."

Michael Harrison, Tate & Lyle SVP, New Product Development

CODEXIS®
PROTEIN ENGINEERING EXPERTS™

Improving Sensitivity and Precision in Molecular Diagnostics



CHALLENGE

Create more sensitive, fluid-based diagnostic tests: earlier, less invasive cancer detection

SOLUTION

- Codexis DNA ligase converts more input DNA to double-ligated library fragments than T4 DNA ligase across a range of sample input concentrations
- Exceptional conversion of low concentration (10 ng) DNA inputs, ideal for liquid biopsy applications
- Codexis DNA ligase achieves maximal substrate conversion within 5 minutes, enabling streamlined NGS workflows

- ✓ Our DNA Ligase is currently being beta tested by selected customers
- ✓ Other Molecular Diagnostics enzyme candidates are currently being engineered

CODEXIS®
PROTEIN ENGINEERING EXPERTS™

Therapeutic Enzyme to Treat Phenylketonuria (PKU)

In the USA ~1:15,000 newborns have PKU, causing lifelong neurocognitive symptoms

CHALLENGE

Besides aggressive dietary control, no available drug treatment for > 80% of PKU patients

SOLUTION

- First CodeEvolver® drug discovery breakthrough
- Stability in GI tract enables convenient oral dosage
- > 50-fold stability improvement, *in vitro*
- Efficacy demonstrated in four preclinical models
- Human trials targeted to start in early 2018

"Many individuals with PKU are eagerly awaiting new therapeutic options. CDX-6114 holds the potential of being an attractive treatment for PKU."

Dr. Gregory Enns, Professor of Pediatrics, Division of Medical Genetics, Stanford University Hospital

CODEXIS®
PROTEIN ENGINEERING EXPERTS™